HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a $12 price target.
February 29, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterated a Buy rating on Revance Therapeutics with a $12 price target.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst could positively influence investor sentiment towards RVNC, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100